Trade Seres Therapeutics Inc - MCRB CFD

Seres Therapeutics Inc Company profile

About Seres Therapeutics Inc

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Seres Therapeutics Inc revenues increased from $33.2M to $144.9M. Net loss decreased 26% to $65.6M. Revenues reflect Collaboration revenue - related party increase from $11.9M to $143.9M. Lower net loss reflects Interest income increase from $946K to $2.9M (income), Interest expense remaining flat at $2.9M (expense).